Clinical Trial

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Study acronym: NeoIpower
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 3, 2021 (before its estimated March 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase II, single-Arm, prospective study of neoadjuvant Icotinib with chemotherapy for the treatment of patients with epidermal growth factor receptor mutation positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer
Trial Details
NCT Number NCT05104788
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Non-Small Cell Lung Cancer
Enrollment 27 participants
Start Date 2021-10-25
Primary Completion 2024-03-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2021-11-03